Table 2.
Distribution frequency of high-mobility group box 1 (HMGB1) genotypes in 579 control individuals and 579 patients with prostate cancer.
| Variables | Controls (n = 579) (%) | Patients (n = 579) (%) | OR (95% CI) † | AOR (95% CI) ‡ |
|---|---|---|---|---|
| rs1412125 | ||||
| TT | 318 (54.9%) | 333 (57.5%) | 1.00 | 1.00 |
| TC | 222 (38.3%) | 209 (36.1%) | 0.899 (0.705–1.147) | 0.757 (0.562–1.021) |
| CC | 39 (6.8%) | 37 (6.4%) | 0.906 (0.563–1.457) | 0.626 (0.354–1.108) |
| TC + CC | 261 (45.1%) | 246 (42.5%) | 0.900 (0.714–1.135) | 0.848 (0.649–1.107) |
| rs2249825 | ||||
| CC | 431 (74.4%) | 438 (75.6%) | 1.00 | 1.00 |
| CG | 139 (24.0%) | 126 (21.8%) | 0.892 (0.677–1.175) | 0.820 (0.587–1.146) |
| GG | 9 (1.6%) | 15 (2.6%) | 1.640 (0.710–3.788) | 1.785 (0.647–4.925) |
| CG + GG | 148 (25.6%) | 141 (24.4%) | 0.937 (0.718–1.223) | 0.874 (0.632–1.208) |
| rs1045411 | ||||
| CC | 353 (61.0%) | 367 (63.4%) | 1.00 | 1.00 |
| CT | 200 (34.5%) | 186 (32.1%) | 0.895 (0.698–1.146) | 0.887 (0.656–1.199) |
| TT | 26 (4.5%) | 26 (4.5%) | 0.962 (0.548–1.689) | 0.847 (0.429–1.672) |
| CT + TT | 226 (39.0%) | 212 (36.6%) | 0.902 (0.711–1.144) | 0.882 (0.661–1.178) |
| rs1360485 | ||||
| TT | 335 (57.9%) | 347 (59.9%) | 1.00 | 1.00 |
| TC | 211 (36.4%) | 199 (34.4%) | 0.911 (0.713–1.163) | 0.900 (0.668–1.213) |
| CC | 33 (5.7%) | 33 (5.7%) | 0.965 (0.582–1.600) | 0.897 (0.486–1.657) |
| TC + CC | 244 (42.1%) | 232 (40.1%) | 0.918 (0.726–1.160) | 0.899 (0.676–1.196) |
† The odds ratios (ORs) with their 95% confidence intervals were estimated by logistic regression models. ‡ The adjusted odds ratios (AORs) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for age.